Gemtuzumab (brand name Mylotarg) is a monoclonal antibody used in the treatment of acute myeloid leukemia (AML). Gemtuzumab targets CD33, a protein found on the surface of myeloid cells, including leukemic cells in AML. By binding to CD33, gemtuzumab may induce antibody-dependent cellular cytotoxicity (ADCC), leading to destruction of CD33-positive leukemia cells. Gemtuzumab is indicated for the treatment of newly diagnosed CD33-positive AML in adults, as well as for relapsed or refractory CD33-positive AML in both adults and pediatric patients.